| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
31,069 |
25,511 |
$609K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
4,320 |
3,870 |
$608K |
| 62323 |
|
2,615 |
2,152 |
$270K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
6,882 |
5,933 |
$252K |
| 64635 |
|
1,199 |
801 |
$220K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
2,429 |
1,953 |
$214K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,337 |
5,191 |
$183K |
| 64636 |
|
1,983 |
781 |
$155K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
5,194 |
1,627 |
$120K |
| 64493 |
|
630 |
458 |
$69K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,196 |
1,059 |
$52K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
411 |
384 |
$46K |
| 99243 |
|
482 |
461 |
$40K |
| 20610 |
|
1,703 |
1,117 |
$39K |
| 64494 |
|
633 |
411 |
$33K |
| 62321 |
|
256 |
215 |
$28K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
3,042 |
2,459 |
$27K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
444 |
388 |
$26K |
| 64495 |
|
374 |
253 |
$21K |
| 73630 |
|
1,561 |
1,234 |
$20K |
| 99406 |
|
3,421 |
2,913 |
$17K |
| 72110 |
|
816 |
652 |
$15K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
72 |
48 |
$13K |
| 99215 |
Prolong outpt/office vis |
218 |
155 |
$10K |
| 27096 |
|
50 |
42 |
$10K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,183 |
959 |
$9K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
34 |
24 |
$7K |
| 73564 |
|
275 |
222 |
$4K |
| 64483 |
|
34 |
28 |
$4K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
770 |
602 |
$4K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
277 |
222 |
$3K |
| 72100 |
|
256 |
202 |
$3K |
| 20930 |
|
31 |
12 |
$2K |
| 97161 |
|
62 |
57 |
$2K |
| 72050 |
|
109 |
97 |
$2K |
| 22853 |
|
49 |
14 |
$2K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
284 |
239 |
$2K |
| 73610 |
|
86 |
73 |
$1K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
137 |
42 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
104 |
81 |
$1K |
| 97162 |
|
13 |
13 |
$505.90 |
| 73110 |
|
49 |
36 |
$485.73 |
| 77002 |
|
15 |
14 |
$480.15 |
| 97022 |
|
55 |
13 |
$340.28 |
| 73502 |
|
15 |
12 |
$240.24 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
18 |
14 |
$186.48 |
| 99442 |
|
27 |
21 |
$170.29 |
| 73030 |
|
12 |
12 |
$167.97 |
| 73560 |
|
12 |
12 |
$153.02 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
66 |
46 |
$115.29 |
| 99441 |
|
15 |
15 |
$85.27 |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
19 |
15 |
$69.83 |
| 36415 |
Collection of venous blood by venipuncture |
15 |
13 |
$41.83 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
13 |
12 |
$3.31 |